Alto Neuroscience (NYSE:ANRO) Now Covered by HC Wainwright

Equities researchers at HC Wainwright began coverage on shares of Alto Neuroscience (NYSE:ANRO) in a research report issued on Monday,Benzinga reports. The firm set a “buy” rating and a $10.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 433.62% from the stock’s previous close.

Separately, William Blair reiterated an “outperform” rating on shares of Alto Neuroscience in a report on Friday, March 21st. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $15.40.

Alto Neuroscience Price Performance

ANRO traded up $0.07 on Monday, reaching $1.87. The company had a trading volume of 128,663 shares, compared to its average volume of 364,651. Alto Neuroscience has a one year low of $1.56 and a one year high of $17.55. The company has a market capitalization of $50.73 million, a P/E ratio of -0.74 and a beta of 2.14. The company has a fifty day moving average of $3.17 and a 200-day moving average of $5.26. The company has a current ratio of 13.10, a quick ratio of 13.09 and a debt-to-equity ratio of 0.05.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.09. As a group, equities research analysts anticipate that Alto Neuroscience will post -2.54 earnings per share for the current year.

Hedge Funds Weigh In On Alto Neuroscience

A number of hedge funds and other institutional investors have recently made changes to their positions in ANRO. Charles Schwab Investment Management Inc. boosted its stake in shares of Alto Neuroscience by 182.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 186,968 shares of the company’s stock valued at $2,139,000 after purchasing an additional 120,779 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Alto Neuroscience by 84.5% during the third quarter. The Manufacturers Life Insurance Company now owns 65,805 shares of the company’s stock worth $753,000 after purchasing an additional 30,135 shares during the period. FMR LLC grew its stake in shares of Alto Neuroscience by 1.4% during the third quarter. FMR LLC now owns 2,363,056 shares of the company’s stock worth $27,033,000 after purchasing an additional 32,040 shares during the period. BNP Paribas Financial Markets lifted its holdings in shares of Alto Neuroscience by 619.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company’s stock valued at $49,000 after purchasing an additional 3,715 shares in the last quarter. Finally, MetLife Investment Management LLC bought a new stake in Alto Neuroscience during the 3rd quarter worth approximately $146,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.